Patents by Inventor Nicolas Barthelemy

Nicolas Barthelemy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20230341421
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: April 24, 2023
    Publication date: October 26, 2023
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • CSF PHOSPHORYLATED TAU AND AMYLOID BETA PROFILES AS BIOMARKERS OF TAUOPATHIES
    Publication number: 20230280357
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues and optionally Ab species to diagnose a subject, guide treatment decisions, and select subjects for clinical trials.
    Type: Application
    Filed: March 31, 2022
    Publication date: September 7, 2023
    Inventors: CHIHIRO SATO, NICOLAS BARTHELEMY, RANDALL BATEMAN
  • Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease
    Publication number: 20230132508
    Abstract: The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 4, 2023
    Applicants: Genentech Inc., Washington University
    Inventors: Kristin Ruth Wildsmith, Balazs Toth, Randall Bateman, Nicolas Barthelemy
  • Methods of treating based on site-specific tau phosphorylation
    Patent number: 11635440
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: April 25, 2023
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • BLOOD-BASED ASSAY FOR DIAGNOSING AND TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20230017557
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: September 10, 2020
    Publication date: January 19, 2023
    Inventors: RANDALL BATEMAN, NICOLAS BARTHELEMY
  • METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20220317136
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: June 17, 2022
    Publication date: October 6, 2022
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF
    Publication number: 20220299527
    Abstract: The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R-tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 22, 2022
    Inventors: RANDALL BATEMAN, CHIHIRO SATO, KANTA HORIE, NICOLAS BARTHELEMY
  • Methods of treating based on site-specific tau phosphorylation
    Patent number: 11402392
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 2, 2022
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • METHODS FOR TREATING TAUOPATHIES
    Publication number: 20220064271
    Abstract: This invention relates to epitope binding agents that specifically bind to tau and methods of use thereof. The disclosure provides immunoassays, kits, and pharmaceutical compositions which include an epitope binding agent that specifically bind to tau. The disclosure provides methods of reducing the spread of tau aggregates and methods of reducing a tauopathy-related pathology.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Inventors: Randall Bateman, David Holtzman, Kanta Horie, Nicolas Barthelemy, Chihiro Sato, Hong Jiang
  • METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20210341495
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 4, 2021
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Methods of treating based on site-specific tau phosphorylation
    Patent number: 11085935
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 10, 2021
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • METHODS OF TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
    Publication number: 20200400689
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Inventors: Nicolas Barthelemy, Randall Bateman